Navigation Links
Idenix Pharmaceuticals Reports First Quarter Financial Results
Date:4/30/2009

CAMBRIDGE, Mass., April 30 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the first quarter ended March 31, 2009. At March 31, 2009, Idenix's cash, cash equivalents and marketable securities totaled $64.5 million.

Business Highlights

  • In the first quarter of 2009, the company announced that it had licensed its NNRTI program for the treatment of HIV/AIDS, including IDX899, to GlaxoSmithKline (GSK) and received a $34 million payment, $17 million of which was a cash payment and the other $17 million representing the purchase of shares of Idenix common stock by GSK. Idenix may also be eligible to receive up to $416 million in development, regulatory and sales milestones, as well as double-digit tiered royalties based on worldwide product sales.
  • In April 2009, data were presented from each of Idenix's hepatitis C programs at the annual meeting of the European Association for the Study of the Liver in Copenhagen, Denmark (see press release dated April 23, 2009 for further details). The company continues to advance its three HCV discovery and development programs, with a nucleoside/tide polymerase inhibitor being evaluated in a proof-of-concept clinical study and non-nucleoside polymerase and protease inhibitors undergoing late-stage preclinical testing.

"Our primary objective at Idenix is to discover and develop the leading HCV antiviral platform," said Jean-Pierre Sommadossi, Ph.D., chairman and chief executive officer of Idenix. "With the licensing of IDX899 to GSK in February of this year and the continued advancement of drug candidates from three major classes of
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
(Date:12/19/2014)... MA (PRWEB) December 19, 2014 Charm ... MRLAFMQ test for the Detection of Aflatoxin M1 in ... to receive independent third party validation. The peer reviewed ... Unit of the Institute for Agricultural and Fisheries Research ... Group. , Aflatoxin B1, the most toxic aflatoxin ...
(Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
(Date:12/19/2014)... Ill. , Dec. 19, 2014 Naurex ... develop novel drugs for diseases of the central nervous ... president and chief executive officer, will present at the ... Riedel,s presentation will take place at 3:00 p.m. PST ... Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... Beckman Coulter,Inc. (NYSE: BEC ), a ... automate, and innovate complex biomedical testing,announced today that ... Business Development, will present at the following,conferences:, ... -- Bank of America 2008 Healthcare Conference on ...
... in physician,s office -, MADISON, N.J., May ... Diagnostics Incorporated (NYSE: DGX ),today announced the ... fecal,immunochemical test, a point-of-care version of the company,s ... sensitivity and,specificity of the laboratory-based InSure FIT test., ...
... CE Mark Approval for First Product, the CorMatrix ... ECM(TM) for Pericardial ... based company dedicated to developing and delivering unique,extracellular matrix (ECM(TM)) ... cardiovascular tissue, announced,today that the company has received 510(k) clearance ...
Cached Biology Technology:Beckman Coulter to Present at Upcoming Healthcare Conferences 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 2Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 3Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 4Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening 5CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 2CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 3CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair 4
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... WINSTON SALEM, N.C. , Dec. 10, 2014  That ... known for quite a while. Hypertension – the medical term ... disease in the early 1800s, and the inflatable cuff that,s ... That doesn,t, however, mean there,s nothing new about hypertension, ... punctured some long-held beliefs about the condition and the best ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... of funding-- dollars drop, in this particular case, for ... faculty and staff. Those declines ultimately impact student ... "Obviously if you,ve had a 30% reduction in funding, ... budget. And so programs are affected," says Colorado ...
... − A new study from the Infant Brain Imaging ... Research at the Children,s Hospital of Philadelphia (CHOP), found ... months in high-risk infants who later develop autism, compared ... "It,s a tremendously exciting finding," said Sarah Paterson, PhD, ...
... SEATTLE Evolutionary biologist Harmit Singh Malik, Ph.D., of ... grant from the Lupus Research Institute to study the ... lupus, an autoimmune disease. , Malik and colleagues want ... causes lupus autoimmunity., "We want to determine whether autoimmunity ...
Cached Biology News:New autism research reveals brain differences at 6 months in infants who develop autism 2Did an evolutionary arms race cause lupus? Biologist Harmit Malik receives grant to try and find out 2
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... instrument engineered to match the speed of ... of research centers worldwide. It uses 1.5 ... ideally suited for high-speed temperature cycling due ... surface-area-to-volume ratio. ,By combining glass capillary tubes ...
... CUL-3 is a member of the family of human ... homologous to the S. cerevisiae cdc53 gene. Cullin-3 is ... It forms a tight complex with cyclin E and ... by protesomes. Cyclin E is an activator of cdk2, ...
Yellow oily liquid. Contains 85% Drakeol 5NF, 15% Arlacel A (mannide monooleate emulsifier). Heat sterilized. Contains zero colony forming units/ml. ...
Biology Products: